Gravity's Rainbow

botany, shoes, books, and justice

Erenumab in Phase III clinical trials for episodic migraine

| 0 comments

Erenumab is a fully human monoclonal antibody specifically designed for the prevention of migraine. Erenumab targets and blocks the Calcitonin Gene-Related Peptide (CGRP) receptor, thought to be pivotal in the genesis of migraine. Erenumab is currently being studied in several large global, randomized, double-blind, placebo-controlled trials to assess its safety and efficacy in migraine prevention. [from the press release for the ARISE study]

Kerrie has a nice breakdown of the results, which look quite encouraging, but not magical.

 

Related Posts Plugin for WordPress, Blogger...

Leave a Reply

Required fields are marked *.